Logo image of CELL

PHENOMEX INC (CELL) Stock Fundamental Analysis

NASDAQ:CELL - Nasdaq - US0843101017 - Common Stock - Currency: USD

0.9981  +0 (+0.31%)

After market: 0.999 +0 (+0.09%)

Fundamental Rating

3

Overall CELL gets a fundamental rating of 3 out of 10. We evaluated CELL against 57 industry peers in the Life Sciences Tools & Services industry. While CELL seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CELL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CELL has reported negative net income.
In the past year CELL has reported a negative cash flow from operations.
In the past 5 years CELL always reported negative net income.
In the past 5 years CELL always reported negative operating cash flow.
CELL Yearly Net Income VS EBIT VS OCF VS FCFCELL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

CELL's Return On Assets of -69.85% is on the low side compared to the rest of the industry. CELL is outperformed by 92.19% of its industry peers.
The Return On Equity of CELL (-111.90%) is worse than 87.50% of its industry peers.
Industry RankSector Rank
ROA -69.85%
ROE -111.9%
ROIC N/A
ROA(3y)-27.59%
ROA(5y)-23.81%
ROE(3y)-40.38%
ROE(5y)-34.8%
ROIC(3y)N/A
ROIC(5y)N/A
CELL Yearly ROA, ROE, ROICCELL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -20 -40 -60

1.3 Margins

Looking at the Gross Margin, with a value of 64.75%, CELL belongs to the top of the industry, outperforming 89.06% of the companies in the same industry.
CELL's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CELL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.73%
GM growth 5YN/A
CELL Yearly Profit, Operating, Gross MarginsCELL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 50 -50 -100

More info and screens

5

2. Health

2.1 Basic Checks

CELL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CELL has been increased compared to 1 year ago.
CELL has a worse debt/assets ratio than last year.
CELL Yearly Shares OutstandingCELL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 20M 40M 60M
CELL Yearly Total Debt VS Total AssetsCELL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

CELL has an Altman-Z score of -3.61. This is a bad value and indicates that CELL is not financially healthy and even has some risk of bankruptcy.
CELL has a worse Altman-Z score (-3.61) than 85.94% of its industry peers.
There is no outstanding debt for CELL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.61
ROIC/WACCN/A
WACC11.88%
CELL Yearly LT Debt VS Equity VS FCFCELL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

A Current Ratio of 2.25 indicates that CELL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.25, CELL is doing worse than 70.31% of the companies in the same industry.
A Quick Ratio of 1.26 indicates that CELL should not have too much problems paying its short term obligations.
CELL has a worse Quick ratio (1.26) than 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 1.26
CELL Yearly Current Assets VS Current LiabilitesCELL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

CELL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.52%.
Looking at the last year, CELL shows a very negative growth in Revenue. The Revenue has decreased by -17.32% in the last year.
CELL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.51% yearly.
EPS 1Y (TTM)-9.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.53%
Revenue 1Y (TTM)-17.32%
Revenue growth 3Y11.51%
Revenue growth 5YN/A
Sales Q2Q%-26.58%

3.2 Future

CELL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.95% yearly.
The Revenue is expected to grow by 20.33% on average over the next years. This is a very strong growth
EPS Next Y17.97%
EPS Next 2Y25.78%
EPS Next 3Y21.68%
EPS Next 5Y15.95%
Revenue Next Year-10.41%
Revenue Next 2Y9.31%
Revenue Next 3Y15.99%
Revenue Next 5Y20.33%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CELL Yearly Revenue VS EstimatesCELL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
CELL Yearly EPS VS EstimatesCELL Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CELL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELL Price Earnings VS Forward Price EarningsCELL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELL Per share dataCELL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as CELL's earnings are expected to grow with 21.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.78%
EPS Next 3Y21.68%

More info and screens

0

5. Dividend

5.1 Amount

CELL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHENOMEX INC

NASDAQ:CELL (9/29/2023, 8:22:41 PM)

After market: 0.999 +0 (+0.09%)

0.9981

+0 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)11-06 2023-11-06/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner Change0%
Market Cap98.79M
Analysts50.91
Price Target1.53 (53.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.91%
Min EPS beat(2)-4.8%
Max EPS beat(2)-1.01%
EPS beat(4)0
Avg EPS beat(4)-15.27%
Min EPS beat(4)-49.99%
Max EPS beat(4)-1.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-9.51%
Min Revenue beat(2)-20.56%
Max Revenue beat(2)1.55%
Revenue beat(4)1
Avg Revenue beat(4)-12.68%
Min Revenue beat(4)-28.89%
Max Revenue beat(4)1.55%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-73.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.38
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 1.11
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0.73
BVpS1.12
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.85%
ROE -111.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.75%
FCFM N/A
ROA(3y)-27.59%
ROA(5y)-23.81%
ROE(3y)-40.38%
ROE(5y)-34.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.73%
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.53%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 1.26
Altman-Z -3.61
F-Score3
WACC11.88%
ROIC/WACCN/A
Cap/Depr(3y)145.66%
Cap/Depr(5y)157.52%
Cap/Sales(3y)11.31%
Cap/Sales(5y)14.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.53%
EPS Next Y17.97%
EPS Next 2Y25.78%
EPS Next 3Y21.68%
EPS Next 5Y15.95%
Revenue 1Y (TTM)-17.32%
Revenue growth 3Y11.51%
Revenue growth 5YN/A
Sales Q2Q%-26.58%
Revenue Next Year-10.41%
Revenue Next 2Y9.31%
Revenue Next 3Y15.99%
Revenue Next 5Y20.33%
EBIT growth 1Y-16.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.51%
EBIT Next 3Y18.4%
EBIT Next 5YN/A
FCF growth 1Y-50.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.31%
OCF growth 3YN/A
OCF growth 5YN/A